Myristica fragrans Extract Inhibits Platelet Desialylation and Activation to Ameliorate Sepsis-Associated Thrombocytopenia in a Murine CLP-Induced Sepsis Model
Authors:
- Seong-Hun JeongSJSeong-Hun Jeong
- Ji-Young ParkJPJi-Young Park
- Young Bae RyuYRYoung Bae Ryu
- Woo Sik KimWKWoo Sik Kim
- In-Chul LeeILIn-Chul Lee
- Ju-Hong KimJKJu-Hong Kim
- Dohoon KimDKDohoon Kim
- Ji-Hye HaJHJi-Hye Ha
- Ba-Wool LeeBLBa-Wool Lee
- Jiyoung NamJNJiyoung Nam
- Kyoung-Oh ChoKCKyoung-Oh Cho
- Hyung-Jun KwonHKHyung-Jun Kwon
Open Access
- 16 May 2023
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (10) , 8863
Abstract
Sepsis, characterized by an uncontrolled host inflammatory response to infections, remains a leading cause of death in critically ill patients worldwide. Sepsis-associated thrombocytopenia (SAT), a common disease in patients with sepsis, is an indicator of disease severity. Therefore, alleviating SAT is an important aspect of sepsis treatment; however, platelet transfusion is the only available treatment strategy for SAT. The pathogenesis of SAT involves increased platelet desialylation and activation. In this study, we investigated the effects of Myristica fragrans ethanol extract (MF) on sepsis and SAT. Desialylation and activation of platelets treated with sialidase and adenosine diphosphate (platelet agonist) were assessed using flow cytometry. The extract inhibited platelet desialylation and activation via inhibiting bacterial sialidase activity in washed platelets. Moreover, MF improved survival and reduced organ damage and inflammation in a mouse model of cecal ligation and puncture (CLP)-induced sepsis. It also prevented platelet desialylation and activation via inhibiting circulating sialidase activity, while maintaining platelet count. Inhibition of platelet desialylation reduces hepatic Ashwell–Morell receptor-mediated platelet clearance, thereby reducing hepatic JAK2/STAT3 phosphorylation and thrombopoietin mRNA expression. This study lays a foundation for the development of plant-derived therapeutics for sepsis and SAT and provides insights into sialidase-inhibition-based sepsis treatment strategies.Keywords
Funding Information
- National Research Council of Science and Technology (CRC21021-100, KRIBB KGM5242322)
This publication has 57 references indexed in Scilit:
- Elevated thrombopoietin in plasma of burned patients without and with sepsis enhances platelet activationJournal of Thrombosis and Haemostasis, 2009
- Immunodesign of experimental sepsis by cecal ligation and punctureNature Protocols, 2008
- Limited Inhibitory Effects of Oseltamivir and Zanamivir on Human SialidasesAntimicrobial Agents and Chemotherapy, 2008
- The Ashwell receptor mitigates the lethal coagulopathy of sepsisNature Medicine, 2008
- Management of sepsis in patients with liver failureCurrent Opinion in Critical Care, 2008
- The molecular mechanisms that control thrombopoiesisJournal of Clinical Investigation, 2005
- The trans -Sialidase from Trypanosoma cruzi Induces Thrombocytopenia during Acute Chagas' Disease by Reducing the Platelet Sialic Acid ContentsInfection and Immunity, 2005
- Hepatoprotective Effect of Myristicin from Nutmeg (Myristica fragrans) on Lipopolysaccharide/d-Galactosamine-Induced Liver InjuryJournal of Agricultural and Food Chemistry, 2003
- Platelet and Leukocyte Activation Correlate with the Severity of Septic Organ DysfunctionShock, 2002
- Evaluation Of The Pharmacological Properties Of Nutmeg Oil In Rats And MicePharmaceutical Biology, 2000